Physician profile
Rohit Kumar Jain
NPI 1922365477
$56,951.66
in general payments reported to CMS, 2019-2025
19 companies · $12K in 2025
The $12K reported for 2025 was more than what 83% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,918 · 2020: $5,389 · 2021: $19K · 2022: $5,884 · 2023: $10K · 2024: $1,113 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Honoraria: $1,838 · Food and Beverage: $1,496 · Travel and Lodging: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,570.00 |
| Honoraria | $1,837.50 |
| Food and Beverage | $1,496.30 |
| Travel and Lodging | $1,418.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $10,236.33 | 2020-2023 | |
| Pfizer INC. | $10,050.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $9,246.26 | 2021-2024 | |
| Gilead Sciences, INC. | $5,774.41 | 2021-2023 | |
| Eli Lilly and Company | $3,313.00 | 2025 | |
| Ares Trading Sa | $3,060.00 | 2023 | Bavencio |
| Immunomedics, INC. | $2,925.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $2,844.52 | 2024-2025 | Erleada, Balversa, Pipeline |
| Novartis Pharmaceuticals Corporation | $2,800.00 | 2025 | |
| Exelixis INC. | $2,543.83 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $1,767.50 | 2025 | |
| Aveo Pharmaceuticals, INC. | $1,603.41 | 2021-2024 | |
| Astellas Pharma US INC | $481.15 | 2020-2025 | Veozah |
| Emd Serono, INC. | $257.67 | 2022-2023 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $29.16 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $19.28 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.